Interview with Dr. Markus Wilhelms, CEO & Co-founder by Greg Mannix, VP, EMEA Business Development, LSN
 Dr. Markus Wilhelms |
 Greg Mannix |
Following their first-place win at the RESI Europe 2025 Innovator’s Pitch Challenge, Dr. Markus Wilhelms, CEO and Co-founder of MOWOOT, discusses their technology, fundraising plans, and what lies ahead for the company.
Greg Mannix (GM): What inspired the development of MOWOOT’s technology, and what unmet need are you addressing?
Markus Wilhelms (MW): Bowel dysfunctions and intestinal transit disorders like chronic constipation affect up to a quarter of the population, often caused by faulty colonic movement patterns. Current treatments are pharmaceutical or invasive and focus on managing symptoms, not addressing the root cause. Our ‘Intermittent Colonic Exoperistalsis’ technology, developed in collaboration with one of Europe’s leading neurorehabilitation hospitals, provides a non-invasive, wearable solution. The MOWOOT device acts as a pacemaker for the large intestine, mobilizing the feces and stimulating proper colonic movement in just 20 minutes a day. This easy-to-use and non-threatening approach offers high clinical response rates and strong patient adherence, without the side effects of conventional treatments.
GM: What stage of fundraising are you currently in, and what types of investors are you hoping to connect with?
MW: Our device is already available in several EU markets, with private & public case-by-case reimbursement secured. We aim for broad public healthcare reimbursement in the UK and Germany by 2025 and are currently raising €10M to support our EU expansion and US market entry in 2026. We are open to discussions with all types of investors, including business angels, family offices, VCs, and strategic corporate investors, as long as we align on deal terms, ticket size and vision.
GM: How has RESI Europe contributed to your fundraising or networking efforts?
MW: RESI Europe provided valuable networking opportunities with investors globally. We had productive meetings during the event as well as on the online platform and are now following up to deepen these conversations.
GM: What was the most valuable aspect of participating in the Innovator’s Pitch Challenge?
MW: Winning the IPC validated our investment opportunity and increased our visibility. It helped us reach investors who might have missed us due to packed schedules, creating additional endorsement and exposure.
GM: What kind of feedback did you receive from the judges or investors during the event?
MW: The feedback on our presentation was very positive, with the jury particularly highlighting the clarity of everything regarding technology, regulatory, and clinical evidence. Most of the questions focused on use of funds, market access strategy and details of reimbursement requirements across different regions, which we were able to address during the Q&A. Given the time constraints of the 6-minute pitch, the Q&A provided a valuable opportunity to fill in any gaps.
GM: How does your team plan to build on the momentum from RESI Europe?
MW: We are actively following up with all new contacts and continuing to receive investor inquiries, thanks to our IPC win. Our data room is prepared, and we expect to move into due diligence with several candidates soon.
GM: What’s next for MOWOOT in the coming 6–12 months?
MW: Over the next 6-12 months, our goal is to secure broad public healthcare reimbursement in the UK and Germany, and we anticipate that scaling in these markets will require robust marketing support. Additionally, we are preparing for a new clinical trial designed to meet the specific reimbursement requirements in France and the US, as confirmed in discussions with local authorities. It’s an exciting period ahead, marking the beginning of our scale-up phase!
Life Science Nation (LSN) is pleased to announce the Global Family Office BioForum (GFOB) return at 
Chris Garabedian
Rick Berenson
Bullfrog AI is at the forefront of integrating artificial intelligence into drug development, helping biotech and pharma companies extract meaningful insights from complex data. Toby Sayre shares how the company’s AI-driven approach enhances decision-making, accelerates therapeutic innovation, and improves success rates. In this interview, he discusses Bullfrog AI’s technology, its role in shaping the future of drug development, and the company’s experience at RESI.
